PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number.

no persope

Sheet 1

Under the Peperwork Reduction Account 995, no perso Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/583,785				
Filing Date	06/19/2006				
First Named Inventor	Seeger				
Art Unit					
Examiner Name	tta Chih-Min Kam				
Attornov Docket Mumber	607027-01				

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (d known)}	Publication Dete MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passeges or Relevant Figures Appear
/CMK	/	^{US-} 4,880,776	11-14-1989	Beecham Group P.L.C.	
75319(15)	1	US-			
		US-			
	ľ	US-			
		US-			

FOREIGN PATENT DOCUMENTS									
	Cite No.1	Foreign Petent Document	Publication Date	Neme of Patentee or Applicent of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ'			
					-	-			
						₽			
	 					H			
	 					T			
	-								

Examiner		Date	00/40/0040
Signature	/Chih Min Kam/	Considered	08/13/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optionel). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standerd ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Traisation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) en application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reducti

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/583,785 INFORMATION DISCLOSURE Filing Date 06/19/2006 STATEMENT BY APPLICANT **First Named Inventor** Seeger Art Unit 1656 444 (Use as many sheets as necessary) Chih-Min Kam **Examiner Name** tho-Attorney Docket Number Sheet 2 607927-01

Examiner Initials* Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		IDELL S., "Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways." Crit. Care Med. (2002) vol. 30, pages 274-280				
		BERTOZZI, P. et al., "Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome." N. Engl. J. Med., (1990) vol. 30, pages 890-897				
		CAMPELL, E.J. et al., "Extracellular matrix injury during lung inflammation." Chest, (1987) vol. 92, pages 161-167				
0000		BURKHARDT, A., "Alveolitis and collapse in the pathogenesis of pulmonary fibrosis." Am. Rev. Respir. Dis. (1989) vol. 140, pages 513-524				
0,0000000000000000000000000000000000000		CREUWELS, L.A.J.M. et al., "The pulmonary surfactant system: Biochemical and clinical aspects." Lung (1997) vol. 175, pages 1-39				
		HAGGSMANN, H.P. et al., "Surfactant-associated proteins: functions and structural variation." Comp. Biochem. Physiol. A: Mol. Integr. Physiol. (2001) vol. 129, pages 91-108.				
		CROUCH, E. et al., "Surfactant proteins A and D and pulmonary host defence." Annu. Rev. Physiol. (2001), vol. 63, pages 521-54.				
9,0000000000000000000000000000000000000		WEAVER, T.E. et al., "Functions of surfactant proteins B and C." Annu. Rev. Physiol. (2001) vol. 63, pages 555-78				
V		SISSON, T.H. et al., "Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes." Human Gene Therapy (1999), vol. 10, pages 2315-2323.				
/CMK./		LEVIN, E.G. et al., "Human hepatoma cell line plasminogen activator." J. Lab. Clin. Med. (1983), vol. 102, pages 500-508.				

Signature /Chih Min Kam/ Considered 08/13/2010	Signature /Chih Min Kam/	Constacted	
--	----------------------------	------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complate, including gathering, preparing, and submitting tha completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent end Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known					
				Application Number	10/583,785		
			CLOSURE	Filing Date	06/19/2006		
STATEMENT BY APPLICANT [First Named Inventor	Seeger		
,,	/sa as many shaats :	as ne	ecessarvi	Art Unit	1656		
(out as many analis as more arry)				Examiner Name	the Chih-Min Kam		
Sheet 3	(of	3	Attorney Docket Number	607927-01		

Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. PETER, K. et al., "Construction and in vitro testing of a novel Fab-Hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor Xa-dependent manner." Cardiovasc. Pharmacol., (2003), vol. 42, pages 237-244					
000000000000000000000000000000000000000		LINDBLADH C. et al., "Use of genetically prepared enzyme conjugates in enzyme immunoassay." Trends Biochem Sci. (1993), vol. 18(8), pages 279-83.					
		SCHERMULY, R.T. et al., "Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (Va/Q) mismatch in a model of acute lung injury." Am. J. Respir. Crit. Care Med. (2000), vol. 161, pages 152-159.					
		CASTELLINO F.J. et al., "Structure and function of the plasminogen/plasmin system." Thromb Haemost (2005), vol. 93, pages 647-54.					
V		DOBROVOLSKY A.B. et al., "The fibrinolysis system: Regulation of activity and physiologic functions of its main components." Biochemistry (Moscow) (2002), vol. 67 (1), pages 99-108	-				
/CMK./		COLLEN D.C. et al., "Thrombolytic agents." Thromb Haemost (2005), vol. 93, pages 627-30.					
,							

Examiner Signature	/Chih Min Kam/	Date Considered	08/13/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fila (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collaction is astimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Tima will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: